Larkin, J. et al. Mixed nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Google Scholar
Hodi, F. S. et al. Improved survival with ipilimumab in sufferers with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Google Scholar
Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung most cancers. N. Engl. J. Med. 378, 1976–1986; erratum 379, 2185 (2018).
Verschoor, Y. L. et al. Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the part 2 PANDA trial. Nat. Med. 30, 519–530 (2024).
Google Scholar
Schmid, P. et al. Occasion-free survival with pembrolizumab in early triple-negative breast most cancers. N. Engl. J. Med. 386, 556–567 (2022).
Google Scholar
Mittendorf, E. A. et al. Neoadjuvant atezolizumab together with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in sufferers with early-stage triple-negative breast most cancers (IMpassion031): a randomised, double-blind, part 3 trial. Lancet 396, 1090–1100 (2020).
Google Scholar
Emens, L. A. et al. Lengthy-term scientific outcomes and biomarker analyses of atezolizumab remedy for sufferers with metastatic triple-negative breast most cancers: a part 1 research. JAMA Oncol. 5, 74–82 (2019).
Google Scholar
Schmid, P. et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers. N. Engl. J. Med. 379, 2108–2121 (2018).
Google Scholar
Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for beforehand untreated domestically recurrent inoperable or metastatic triple-negative breast most cancers (KEYNOTE-355): a randomised, placebo-controlled, double-blind, part 3 scientific trial. Lancet 396, 1817–1828 (2020).
Google Scholar
Emens, L. A. et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers: biomarker analysis of the IMpassion130 research. J. Natl Most cancers Inst. 113, 1005–1016 (2021).
Google Scholar
Loibl, S. et al. A randomised part II research investigating durvalumab along with an anthracycline taxane-based neoadjuvant remedy in early triple-negative breast most cancers: scientific outcomes and biomarker evaluation of GeparNuevo research. Ann. Oncol. 30, 1279–1288 (2019).
Google Scholar
Bachelot, T. et al. Durvalumab in comparison with upkeep chemotherapy in metastatic breast most cancers: the randomized part II SAFIR02-BREAST IMMUNO trial. Nat. Med. 27, 250–255 (2021).
Google Scholar
Loi, S. et al. Affiliation between biomarkers and scientific outcomes of pembrolizumab monotherapy in sufferers with metastatic triple-negative breast most cancers: KEYNOTE-086 exploratory evaluation. JCO Summary. Oncol. 7, e2200317 (2023).
Google Scholar
Voorwerk, L. et al. Immune induction methods in metastatic triple-negative breast most cancers to reinforce the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920–928 (2019).
Google Scholar
Nederlof, I. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast most cancers: a part 2 adaptive trial. Nat. Med. 30, 3223–3235 (2024).
Google Scholar
Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast most cancers. Nature 621, 868–876 (2023).
Google Scholar
Elhanani, O., Ben-Uri, R. & Keren, L. Spatial profiling applied sciences illuminate the tumor microenvironment. Most cancers Cell 41, 404–420 (2023).
Google Scholar
Jackson, H. W. et al. The one-cell pathology panorama of breast most cancers. Nature 578, 615–620 (2020).
Google Scholar
Keren, L. et al. A structured tumor–immune microenvironment in triple unfavourable breast most cancers revealed by multiplexed ion beam imaging. Cell 174, 1373–1387.e19 (2018).
Google Scholar
Blomberg, O. S. et al. IL-5-producing CD4 T cells and eosinophils cooperate to reinforce response to immune checkpoint blockade in breast most cancers. Most cancers Cell 41, 106–123.e10 (2023).
Google Scholar
Angelo, M. et al. Multiplexed ion beam imaging of human breast tumors. Nat. Med. 20, 436–442 (2014).
Google Scholar
Greenwald, N. F. et al. Entire-cell segmentation of tissue photos with human-level efficiency utilizing large-scale information annotation and deep studying. Nat. Biotechnol. 40, 555–565 (2022).
Google Scholar
Liu, C. C. et al. Strong phenotyping of extremely multiplexed tissue imaging information utilizing pixel-level clustering. Nat. Commun. 14, 4618 (2023).
Google Scholar
da Silva, I. P. et al. Reversal of NK-cell exhaustion in superior melanoma by TIM-3 blockade. Most cancers Immunol. Res. 2, 410–422 (2014).
Google Scholar
Li, Y. et al. TIM-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates being pregnant loss. Sci. Sign. 10, eaah4323 (2017).
Google Scholar
Zhang, J. et al. Sequential actions of EOMES and T-bet promote stepwise maturation of pure killer cells. Nat. Commun. 12, 5446 (2021).
Google Scholar
Costa, A. et al. Fibroblast heterogeneity and immunosuppressive surroundings in human breast most cancers. Most cancers Cell 33, 463–479.e10 (2018).
Google Scholar
Wang, C. et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast most cancers: a single-arm part II trial. Nat. Commun. 14, 6654 (2023).
Google Scholar
van der Leun, A. M., Thommen, D. S. & Schumacher, T. N. CD8+ T cell states in human most cancers: insights from single-cell evaluation. Nat. Rev. Most cancers 20, 218–232 (2020).
Google Scholar
Savas, P. et al. Single-cell profiling of breast most cancers T cells reveals a tissue-resident reminiscence subset related to improved prognosis. Nat. Med. 24, 986–993 (2018).
Google Scholar
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set assortment. Cell Syst. 1, 417–425 (2015).
Google Scholar
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Google Scholar
Ali, H. R. et al. Imaging mass cytometry and multiplatform genomics outline the phenogenomic panorama of breast most cancers. Nat. Most cancers 1, 163–175 (2020).
Google Scholar
Tibshirani, R. Regression shrinkage and choice by way of the Lasso. J. R. Stat. Soc. B 58, 267–288 (1996).
Google Scholar
McNamara, Okay. L. et al. Spatial proteomic characterization of HER2-positive breast tumors via neoadjuvant remedy predicts response. Nat. Most cancers 2, 400–413 (2021).
Google Scholar
Chen, L. et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Most cancers Discov. 8, 1156–1175 (2018).
Google Scholar
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors related to native immune cytolytic exercise. Cell 160, 48–61 (2015).
Google Scholar
Liu, B. et al. Temporal single-cell tracing reveals clonal revival and enlargement of precursor exhausted T cells throughout anti-PD-1 remedy in lung most cancers. Nat. Most cancers 3, 108–121 (2022).
Google Scholar
Wu, T. D. et al. Peripheral T cell enlargement predicts tumour infiltration and scientific response. Nature 579, 274–278 (2020).
Google Scholar
Oliveira, G. & Wu, C. J. Dynamics and specificities of T cells in most cancers immunotherapy. Nat. Rev. Most cancers 23, 295–316 (2023).
Google Scholar
Luoma, A. M. et al. Tissue-resident reminiscence and circulating T cells are early responders to pre-surgical most cancers immunotherapy. Cell 185, 2918–2935.e29 (2022).
Google Scholar
Yost, Okay. E. et al. Clonal substitute of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
Google Scholar
Shiao, S. L. et al. Single-cell and spatial profiling determine three response trajectories to pembrolizumab and radiation remedy in triple unfavourable breast most cancers. Most cancers Cell 42, 70–84.e8 (2024).
Google Scholar
Denkert, C. et al. Tumour-infiltrating lymphocytes and prognosis in numerous subtypes of breast most cancers: a pooled evaluation of 3771 sufferers handled with neoadjuvant remedy. Lancet Oncol. 19, 40–50 (2018).
Google Scholar
Geurts, V. C. M. et al. Tumor-infiltrating lymphocytes in sufferers with stage I triple-negative breast most cancers untreated with chemotherapy. JAMA Oncol. 10, 1077–1086 (2024).
Google Scholar
Loi, S. et al. Tumor-infiltrating lymphocytes and prognosis: a pooled particular person affected person evaluation of early-stage triple-negative breast cancers. J. Clin. Oncol. 37, 559–569 (2019).
Google Scholar
Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Remedy panorama of triple-negative breast most cancers—expanded choices, evolving wants. Nat. Rev. Clin. Oncol. 19, 91–113 (2022).
Google Scholar
Bidard, F.-C. et al. Change to fulvestrant and palbociclib versus no change in superior breast most cancers with rising ESR1 mutation throughout aromatase inhibitor and palbociclib remedy (PADA-1): a randomised, open-label, multicentre, part 3 trial. Lancet Oncol. 23, 1367–1377 (2022).
Google Scholar
Bassez, A. et al. A single-cell map of intratumoral modifications throughout anti-PD1 therapy of sufferers with breast most cancers. Nat. Med. 27, 820–832 (2021).
Google Scholar
Ribeiro, J. M. et al. 156TiP Affect of neoadjuvant immunotherapy in early stage breast most cancers earlier than commonplace remedy (BIS-Program). ESMO Open 8, 101495 (2023).
Google Scholar
Simon, R. Optimum two-stage designs for part II scientific trials. Management. Clin. Trials 10, 1–10 (1989).
Google Scholar
Huang, M. et al. Affiliation of pathologic full response with long-term survival outcomes in triple-negative breast most cancers: a meta-analysis. Most cancers Res. 80, 5427–5434 (2020).
Google Scholar
Cortazar, P. et al. Pathological full response and long-term scientific profit in breast most cancers: the CTNeoBC pooled evaluation. Lancet 384, 164–172 (2014).
Google Scholar
Schwartz, L. H. et al. RECIST 1.1-Replace and clarification: from the RECIST committee. Eur. J. Most cancers 62, 132–137 (2016).
Google Scholar
Seymour, L. et al. iRECIST: tips for response standards to be used in trials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).
Google Scholar
Risom, T. et al. Transition to invasive breast most cancers is related to progressive modifications within the construction and composition of tumor stroma. Cell 185, 299–310.e18 (2022).
Google Scholar
McCaffrey, E. F. et al. The immunoregulatory panorama of human tuberculosis granulomas. Nat. Immunol. 23, 318–329 (2022).
Google Scholar
Liu, C. C. et al. Reproducible, high-dimensional imaging in archival human tissue by multiplexed ion beam imaging by time-of-flight (MIBI-TOF). Lab. Make investments. 102, 762–770 (2022).
Google Scholar
Bosse, M. et al. MIBI and IHC options. protocols.io (2021).
Bosse, M. IHC staining V.1. protocols.io (2021).
Bosse, M. et al. MIBI staining V.5. protocols.io (2022).
Bosse, M. et al. Staining sequenza. protocols.io (2021).
Camacho, C. et al. Antibody lyophilization. protocols.io (2021).
Greenwald, N. et al. Greenwald, Nederlof et al prolonged strategies V.2. protocols.io (2025).
Medina-Martínez, J. S. et al. Isabl Platform, a digital biobank for processing multimodal affected person information. BMC Bioinformatics 21, 549 (2020).
Google Scholar
Li, H. & Durbin, R. Quick and correct brief learn alignment with Burrows–Wheeler rework. Bioinformatics 25, 1754–1760 (2009).
Google Scholar
Okonechnikov, Okay., Conesa, A. & García-Alcalde, F. Qualimap 2: superior multi-sample high quality management for high-throughput sequencing information. Bioinformatics 32, 292–294 (2016).
Google Scholar
Benjamin, D. et al. Calling somatic SNVs and indels with Mutect2. Preprint at bioRxiv (2019).
Kim, S. et al. Strelka2: quick and correct calling of germline and somatic variants. Nat. Strategies 15, 591–594 (2018).
Google Scholar
Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA restore deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
Google Scholar
Shen, R. & Seshan, V. E. FACETS: allele-specific copy quantity and clonal heterogeneity evaluation instrument for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).
Google Scholar
Ali, H. R. et al. Genome-driven built-in classification of breast most cancers validated in over 7,500 samples. Genome Biol. 15, 431 (2014).
Google Scholar
Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing information. Bioinformatics 30, 3310–3316 (2014).
Google Scholar
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Google Scholar
Richman, L. P., Vonderheide, R. H. & Rech, A. J. Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade. Cell Syst. 9, 375–382 (2019).
Google Scholar
Ayers, M. et al. IFN-γ-related mRNA profile predicts scientific response to PD-1 blockade. J. Clin. Make investments. 127, 2930–2940 (2017).
Google Scholar
Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Most cancers Cell 39, 845–865.e7 (2021).
Google Scholar
Shah, S. P. et al. The clonal and mutational evolution spectrum of major triple-negative breast cancers. Nature 486, 395–399 (2012).
Google Scholar
Lehmann, B. D. et al. Identification of human triple-negative breast most cancers subtypes and preclinical fashions for choice of focused therapies. J. Clin. Make investments. 121, 2750–2767 (2011).
Google Scholar
van den Eynden, J., Jiménez-Sánchez, A., Miller, M. L. & Larsson, E. Lack of detectable neoantigen depletion indicators within the untreated most cancers genome. Nat. Genet. 51, 1741–1748 (2019).
Google Scholar
Fang, Z. & Peltz, G. An automatic multi-modal graph-based pipeline for mouse genetic discovery. Bioinformatics 38, 3385–3394 (2022).
Google Scholar
Tietscher, S. et al. A complete single-cell map of T cell exhaustion-associated immune environments in human breast most cancers. Nat. Commun. 14, 98 (2023).
Google Scholar
Doering, T. A. et al. Community evaluation reveals centrally linked genes and pathways concerned in CD8+ T cell exhaustion versus reminiscence. Immunity 37, 1130–1144 (2012).
Google Scholar
Xu, L. et al. A complete single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 remedy response. Cell Rep. Med. 5, 101511 (2024).
Google Scholar
Newman, A. M. et al. Figuring out cell sort abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773–782 (2019).
Google Scholar
Greenwald, N. et al. Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition. Zenodo (2025).
